This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Bronchial carcinoid tumours

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The term bronchial adenoma covers a variety of tumours, of which approximately 90% are carcinoid tumours arising from cells of the APUD series.

These arise within large bronchi and typically, affect adults under the age of 45 years.

They are soft, fleshy nodules, and macroscopically, produce a dumb bell appearance. Histologically, the cells have a packeted architecture. The cells contain large numbers of dense-core agentaffin granules and secrete a variety of biogenic amines, especially serotonin.

Common clinical features include cough, haemoptysis (the tumour is vascular and bleeds easily), breathlessness, unilateral wheeze and recurrent infections. The condition may be mistaken for asthma because of wheezing dyspnoea.

The tumour is generally not visible on chest X-ray. The most common radiological abnormality is volume loss or lobar collapse. Diagnosis is generally made as a result of bronchoscopy.

Surgical resection is the treatment of choice.

Bronchial carcinoids are low grade malignancies and show a good prognosis, with an 80% 5 year survival rate.

Only rarely, does the carcinoid syndrome occur.


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.